


Product Name : ABBV-744
Cat. No. : PC-35172
CAS No. : 2138861-99-9
Molecular Formula : C₂₈H₃₀FN₃O₄
Molecular Weight : 491.563
Target : Bromodomain
Solubility : 10 mM in DMSO



1. Faivre EJ, et al. **Nature**. 2020 Feb;578(7794):306-310.
2. Sheppard GS, et al. **J Med Chem**. 2020 May

Biological Activity

ABBV-744 (ABBV744) is a highly potent and selective inhibitor of the **BD2 domain of BET family** proteins with IC₅₀ of 4-18 nM for BD2 of BRD2, BRD3, BRD4 and BRDT.

ABBV-744 displayed >250-fold differential binding preference for BDII over BDI and excellent drug-like properties.

ABBV-744 inhibited SARS-CoV-2 replication in Syrian hamsters, potently blocked endogenous ACE2 expression and SARS-CoV-2 infection of human cells, highlighting the potential of BRD2 as a novel therapeutic target for COVID-19.

ABBV-744 displayed significant antiproliferative activities largely although not exclusively in cancer cell lines derived from acute myeloid leukemia and androgen receptor positive prostate cancer.

ABBV-744 demonstrated antitumor efficacy in acute myeloid leukemia xenograft models with an improved therapeutic index compared with the pan-BET inhibitor ABBV-075. enhanced the antitumor efficacy of BCL-2 inhibitor, venetoclax.

References

28;63(10):5585-5623.
3. Fakhar Z, et al. **Sci Rep**. 2021 Jan 8;11(1):234.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com